Australia markets open in 7 hours 38 minutes

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
290.08-1.84 (-0.63%)
At close: 04:00PM EST
289.01 -1.07 (-0.37%)
After hours: 07:28PM EST
Full screen
Trade prices are not sourced from all markets
Previous close291.92
Open292.36
Bid279.00 x 800
Ask290.66 x 2200
Day's range289.94 - 295.89
52-week range187.16 - 311.88
Volume894,286
Avg. volume1,228,142
Market cap41.772B
Beta (5Y monthly)0.21
PE ratio (TTM)14.91
EPS (TTM)19.45
Earnings date15 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est322.30
  • Zacks

    Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

    Biogen (BIIB) and Eisai jointly announce that EMA accepts lecanemab's marketing authorization application (MAA) for the treatment of patients with early-stage Alzheimer's disease, for review.

  • GlobeNewswire

    Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

    TOKYO and CAMBRIDGE, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the European Medicines Agency (EMA) has accepted a marketing authorization application (MAA) for lecanemab (Brand Name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril* antibody, for the treatment of

  • Motley Fool

    Is Biogen Stock a Buy Now?

    Moving new medicines to the market can sometimes make biopharmaceutical companies tons of returns. Biogen (NASDAQ: BIIB) just scored a major new drug approval for an Alzheimer's disease therapy, so investors are understandably rushing to evaluate whether to buy the stock. One key factor that could drive Biogen's outperformance in the next few years is the launch of a new neurology medicine.